XML 52 R35.htm IDEA: XBRL DOCUMENT v3.24.1

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of Stock Options Issued and Outstanding Activities

Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows:

Schedule of Stock Options Issued and Outstanding Activities

		Number of Stock Options				Weighted Average Exercise Price				Remaining Contractual Term (Years)				Intrinsic Value(2)
Outstanding stock options at December 31, 2021			1,419,242			$	0.73				7.0
Granted(1)			2,365,000			$	3.68
Exercised			(965,342	)		$	0.72
Forfeited			(253,523	)		$	3.83
Outstanding stock options at December 31, 2022			2,565,377			$	3.14				8.3			$	428
Granted(1)			3,618,000			$	1.32
Exercised			—			$	—
Forfeited			(678,994	)		$	2.75
Outstanding stock options at December 31, 2023(3)			5,504,383			$	2.00				8.5			$	765
Vested and exercisable stock options at December 31, 2023			2,339,527			$	2.30				7.8			$	529

(1)	Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.
(2)	The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of December 31, 2023 and December 31, 2022 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price.
(3)	The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of December 31, 2023 and December 31, 2022.

Schedule of Restricted Stock Award Activity

Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows:

 Schedule of Restricted Stock Award Activity 

		Number of Restricted Stock Awards				Weighted Average Grant Date Fair Value
Unvested restricted stock awards as of December 31, 2021			1,940,740			$	12.76
Granted			320,000				4.53
Vested			(169,320	)			13.48
Forfeited			—				—
Unvested restricted stock awards as of December 31, 2022(1)			2,091,420			$	11.44
Granted			550,000				1.29
Vested			(303,980	)			11.95
Forfeited			—				—
Unvested restricted stock awards as of December 31, 2023			2,337,440			$	8.99

⁽¹⁾ The unvested restricted stock awards presented in the table above, are inclusive of 50,000 restricted stock awards granted outside the Lucid Diagnostics 2018 Equity Plan as of December 31, 2022. These 50,000 restricted stock awards were fully vested during the year ended December 31, 2023.

Schedule of Stock-Based Compensation Expense

The stock-based compensation expense recognized by the Company for both the Lucid Diagnostics 2018 Equity Plan and the PAVmed 2014 Equity Plan, for the periods indicated, was as follows: 

Schedule of Stock-Based Compensation Expense

		2023				2022
		Years Ended December 31,
		2023				2022
Lucid Diagnostics 2018 Equity Plan – cost of revenue		$	63			$	13
Lucid Diagnostics 2018 Equity Plan – sales and marketing			948				968
Lucid Diagnostics 2018 Equity Plan - general and administrative			4,455				12,691
Lucid Diagnostics 2018 Equity Plan - research and development			296				187
PAVmed 2014 Equity Plan - cost of revenue			37				3
PAVmed 2014 Equity Plan - sales and marketing			463				654
PAVmed 2014 Equity Plan - general and administrative			173				262
PAVmed 2014 Equity Plan - research and development			387				213
Total stock-based compensation expense		$	6,822			$	14,991

Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period

As of December 31, 2023, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the Lucid Diagnostics 2018 Equity Plan and the PAVmed 2014 Equity Plan, as discussed above, is as follows:

Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period

		Unrecognized Expense				Weighted Average Remaining Service Period (Years)
Lucid Diagnostics 2018 Equity Plan
Stock Options		$	3,566				2.0
Restricted Stock Awards		$	1,167				2.2
PAVmed 2014 Equity Plan
Stock Options		$	432				2.1

Schedule of Stock-based Compensation Valuation Assumptions

Schedule of Stock-based Compensation Valuation Assumptions

		2023				2022
		Years Ended December 31,
		2023				2022
Expected term of stock options (in years)			5.6				5.6
Expected stock price volatility			74	%			71	%
Risk free interest rate			3.9	%			2.1	%
Expected dividend yield			—	%			—	%

X

- Definition

Schedule of unrecognized compensation expense and weighted average remaining service period [Table Text Block].

+ References

No definition available.

+ Details

Name:	LUCD_ScheduleOfUnrecognizedCompensationExpenseAndWeightedAverageRemainingServicePeriodTableTextBlock
Namespace Prefix:	LUCD_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Subparagraph (f)(2)
-Name Accounting Standards Codification
-Paragraph 2
-Section 50
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration